417 related articles for article (PubMed ID: 33230180)
21. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
22. In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Main Protease among a PubChem Database of Avian Infectious Bronchitis Virus 3CLPro Inhibitors.
Soulère L; Barbier T; Queneau Y
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371536
[TBL] [Abstract][Full Text] [Related]
23. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
[TBL] [Abstract][Full Text] [Related]
24. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
25. Potential SARS-CoV-2 protease M
Kouznetsova VL; Huang DZ; Tsigelny IF
Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
28. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
Du A; Zheng R; Disoma C; Li S; Chen Z; Li S; Liu P; Zhou Y; Shen Y; Liu S; Zhang Y; Dong Z; Yang Q; Alsaadawe M; Razzaq A; Peng Y; Chen X; Hu L; Peng J; Zhang Q; Jiang T; Mo L; Li S; Xia Z
Int J Biol Macromol; 2021 Apr; 176():1-12. PubMed ID: 33548314
[TBL] [Abstract][Full Text] [Related]
29. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
[TBL] [Abstract][Full Text] [Related]
30. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
Noroozi Tiyoula F; Aryapour H
PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
[TBL] [Abstract][Full Text] [Related]
31. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
32. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
Kwofie SK; Broni E; Asiedu SO; Kwarko GB; Dankwa B; Enninful KS; Tiburu EK; Wilson MD
Molecules; 2021 Jan; 26(2):. PubMed ID: 33466743
[TBL] [Abstract][Full Text] [Related]
33. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
34. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
[TBL] [Abstract][Full Text] [Related]
35. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
[No Abstract] [Full Text] [Related]
36. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
37. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
38. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
[TBL] [Abstract][Full Text] [Related]
39. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
Wang Y; Gao Q; Yao P; Yao Q; Zhang J
J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
[TBL] [Abstract][Full Text] [Related]
40. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
